Development and applications of a real-time quantitative RT-PCR method (QRT-PCR) for BRCA1 mRNA

被引:24
作者
Kroupis, C
Stathopoulou, A
Zygalaki, E
Ferekidou, L
Talieri, M
Lianidou, ES [1 ]
机构
[1] Univ Athens, Analyt Chem Lab, Dept Chem, GR-15771 Athens, Greece
[2] St Savas Hosp, Papanicolaou Res Ctr Oncol, Athens 11522, Greece
关键词
BRCA1; real-time QRT-PCR; antineoplastic agents; gamma irradiation;
D O I
10.1016/j.clinbiochem.2004.09.012
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Objectives: To develop a real-time quantitative RT-PCR method for BRCA1 mRNA and then use it for the study of BRCA1 gene expression in human MCF-7 breast cancer cells after their exposure to antieoplastic agents and gamma irradiation. Design and methods: The developed QRT-PCR method is based on the real-time monitoring of a fluorescein-labeled TaqMan probe, specific for BRCA1 mRNA, during PCR in the LIghtCycler. A BRCA1 PCR amplicon was purified, quantitated and used as a standard of known concentration for the development and analytical evaluation of the assay. The method was applied to study the alteration of BRCA1 gene expression after exposure to taxol, doxorubicin, 5-fluorouracil, etoposide or gamma irradiation in human MCF-7 breast cancer cells. Results: The developed method is quantitative, highly specific for mRNA and highly sensitive (detection limit of 4 BRCA1 copies per mug of total RNA). We observed a reduction of BRCA1 expression for all antineoplastic agents used, while the gamma irradiated MCF-7 cells had an increase of expression with a peak at the 10 Gy dose. Conclusions: The developed BRCA1 QRT-PCR method is quantitative, highly sensitive and specific. The proposed method is rapid, automated, and cost effective and can be used to study BRCA1 expression in a variety of clinical samples. (C) 2004 The Canadian Society of Clinical Chemists. All rights reserved.
引用
收藏
页码:50 / 57
页数:8
相关论文
共 39 条
[1]   Regulation of BRCA1 and BRCA2 expression in human breast cancer cells by DNA-damaging agents [J].
Andres, JL ;
Fan, SJ ;
Turkel, GJ ;
Wang, JA ;
Twu, NF ;
Yuan, RQ ;
Lamszus, K ;
Goldberg, ID ;
Rosen, EM .
ONCOGENE, 1998, 16 (17) :2229-2241
[2]  
Aunoble B, 2001, ONCOL REP, V8, P663
[3]  
Bernard PS, 2002, CLIN CHEM, V48, P1178
[4]   Increased expression of BRCA1 mRNA predicts favorable response to anthracycline-containing chemotherapy in breast cancers [J].
Egawa, C ;
Motomura, K ;
Miyoshi, Y ;
Takamura, Y ;
Taguchi, T ;
Tamaki, Y ;
Inaji, H ;
Koyama, H ;
Noguchi, S .
BREAST CANCER RESEARCH AND TREATMENT, 2003, 78 (01) :45-50
[5]  
Egawa C, 2001, INT J CANCER, V95, P255, DOI 10.1002/1097-0215(20010720)95:4<255::AID-IJC1043>3.0.CO
[6]  
2-O
[7]   Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors [J].
Esteller, M ;
Silva, JM ;
Dominguez, G ;
Bonilla, F ;
Matias-Guiu, X ;
Lerma, E ;
Bussaglia, E ;
Prat, J ;
Harkes, IC ;
Repasky, EA ;
Gabrielson, E ;
Schutte, M ;
Baylin, SB ;
Herman, JG .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (07) :564-569
[8]  
Fan SJ, 1998, INT J CANCER, V77, P600, DOI 10.1002/(SICI)1097-0215(19980812)77:4<600::AID-IJC21>3.0.CO
[9]  
2-8
[10]   Real-time quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) for the measurement of prostate-specific antigen mRNA in the peripheral blood of patients with prostate carcinoma using the TaqMan™ detection system [J].
Gelmini, S ;
Tricarico, C ;
Vona, G ;
Livi, L ;
Della Melina, A ;
Semi, S ;
Cellai, E ;
Magrini, S ;
Villari, D ;
Carini, M ;
Serio, M ;
Forti, G ;
Pazzagli, M ;
Orlando, C .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2001, 39 (05) :385-391